Late-course accelerated Hyperfractionation vs. Conventional Fraction Radiotherapy under precise technology plus Concurrent Chemotherapy for Esophageal Squamous Cell Carcinoma: comparison of efficacy and side effects

doi:10.7150/jca.41012

	Late-course accelerated Hyperfractionation vs. Conventional Fraction Radiotherapy under precise technology plus Concurrent Chemotherapy for Esophageal Squamous Cell Carcinoma: comparison of efficacy and side effects
	Luo, Hongtao 1,2; Wei, Shihong 2; Wang, Xiaohu 1,2,5; Liu, Ruifeng 2; Zhang, Qiuning 4,5; Yang, Zhen 3; Li, Zheng 4; Wei, Xiyi 2; Qi, Yuexiao 2; Xu, Lijun 2
刊名	JOURNAL OF CANCER
	2020
卷号	11 期号:10 页码:3020-3026
关键词	Esophageal cancer late course accelerated hyperfractionation Intensity-modulated radiotherapy Image-guided radiotherapy concurrent chemoradiotherapy
ISSN号	1837-9664
DOI	10.7150/jca.41012
通讯作者	Wang, Xiaohu(xhwanggansu@163.com)
英文摘要	Background: The accelerated reproliferation of esophageal squamous cell carcinoma (ESCC) after radiation contributes to conventional fraction radiotherapy (CFRT) failure. Late course accelerated hyperfractionated radiotherapy (LCAHFRT) can improve the long-term survival of esophageal cancer patients in China but is associated with a high rate of side effects due to the large exposure field of two-dimensional treatment and drug toxicity. Intensity-modulated radiotherapy (IMRT) can increase the tumor dose while decreasing the normal tissue dose. Therefore, we compared the outcomes and side effects of LCAHFIMRT plus concurrent chemotherapy (CT) and CFIMRT plus CT for ESCC. Methods and Materials: Between 2013 and 2016, 114 eligible patients with ESCC were recruited and randomly assigned to receive LCAHFIMRT+CT (58 patients) or CFIMRT+CT (56 patients) by a linear accelerator (6-MV X-ray) under image guidance. Two cycles of CT with cisplatin and docetaxel were also administered. Results: The complete response (CR) rates were 79.3% and 61.8% in the LCAHFIMRT+CT and CFIMRT+CT groups, respectively (P=0.041). The median duration of local control times was 31.0 +/- 1.9 months for the LCAHFIMRT+CT group and 24.0 +/- 3.3 months for the CFIMRT+CT groups,and the 1-, 2-, and 3-year local control rates were 86.2%, 63.8%, and 41.4% and 85.7%, 51.8%, and 32.1% for the LCAHFIMRT+CT and CFIMRT+CT groups (P=0.240), respectively. The median survival times were 34.0 +/- 1.1 months for the LCAHFIMRT+CT group and 28.0.0 +/- 3.7 months for the CFIMRT groups,and the 1-, 2-, and 3-year survival rates were 87.9%, 74.1%, and 44.8% and 87.5%, 60.7%, and 39.3% for the LCAHFIMRT+CT and CFIMRT+CT groups, respectively (P=0.405). The incidence of side effects was not significantly different between the two groups. Local recurrence and uncontrolled disease resulted in more deaths in the CFIMRT+CT group than in the LCAHFIMRT+CT group (58.9% vs. 39.7%) (P=0.040). Conclusion: For ESCC patients, LCAHFRT delivered by image-guided intensity-modulated techniques Plus Concurrent Chemotherapy with cisplatin and docetaxel keeps safety and high CR rate, as well as local control and long-term survival rates.
资助项目	2017 Lanzhou Talent Innovation and Entrepreneurship Project Funding ; Key Technologies for the Basic and Clinical Application of Domestic Heavy Ion Accelerator for Tumor Treatment[2017-RC-23] ; Young Creative Talents of Gansu Project in Gansu Province[[2016] 97] ; Science and Technology Support Program of Gansu Provincial Science and Technology Department[[2016] 1604FKCA109] ; Gansu Provincial Health sector management research project[[2019] 31]
WOS关键词	RADIATION-THERAPY ; CANCER STATISTICS ; LONG-TERM ; DOCETAXEL ; 5-FLUOROURACIL ; CISPLATIN ; TRIAL ; JAPAN ; CHINA
WOS研究方向	Oncology
语种	英语
出版者	IVYSPRING INT PUBL
WOS记录号	WOS:000518772600028
资助机构	2017 Lanzhou Talent Innovation and Entrepreneurship Project Funding ; Key Technologies for the Basic and Clinical Application of Domestic Heavy Ion Accelerator for Tumor Treatment ; Young Creative Talents of Gansu Project in Gansu Province ; Science and Technology Support Program of Gansu Provincial Science and Technology Department ; Gansu Provincial Health sector management research project
内容类型	期刊论文
源URL	[http://119.78.100.186/handle/113462/140942]
专题	中国科学院近代物理研究所
通讯作者	Wang, Xiaohu
作者单位	1.Lanzhou Univ, Clin Med Coll 1, Lanzhou 730000, Peoples R China 2.Gansu Prov Canc Hosp, Lanzhou 730050, Peoples R China 3.Lanzhou Univ, Basic Med Coll, Lanzhou 730000, Peoples R China 4.Lanzhou Heavy Ion Hosp, Lanzhou 730000, Peoples R China 5.Chinese Acad Sci, Inst Modern Phys, Lanzhou 730000, Peoples R China
推荐引用方式 GB/T 7714	Luo, Hongtao,Wei, Shihong,Wang, Xiaohu,et al. Late-course accelerated Hyperfractionation vs. Conventional Fraction Radiotherapy under precise technology plus Concurrent Chemotherapy for Esophageal Squamous Cell Carcinoma: comparison of efficacy and side effects[J]. JOURNAL OF CANCER,2020,11(10):3020-3026.
APA	Luo, Hongtao.,Wei, Shihong.,Wang, Xiaohu.,Liu, Ruifeng.,Zhang, Qiuning.,...&Xu, Lijun.(2020).Late-course accelerated Hyperfractionation vs. Conventional Fraction Radiotherapy under precise technology plus Concurrent Chemotherapy for Esophageal Squamous Cell Carcinoma: comparison of efficacy and side effects.JOURNAL OF CANCER,11(10),3020-3026.
MLA	Luo, Hongtao,et al."Late-course accelerated Hyperfractionation vs. Conventional Fraction Radiotherapy under precise technology plus Concurrent Chemotherapy for Esophageal Squamous Cell Carcinoma: comparison of efficacy and side effects".JOURNAL OF CANCER 11.10(2020):3020-3026.